4 news items
Galapagos reports first quarter 2024 financial results
GLPG
2 May 24
candidates due to safety or efficacy concerns or other reasons), risks related to the acquisitions of CellPoint and AboundBio, including the risk that we may
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
GLPG
4 Apr 24
-label, multi-center studies designed to assess the safety, efficacy and feasibility of point-of-care manufactured GLPG5101 and GLPG5201 in patients
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
GLPG
22 Feb 24
escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of FMC-376 in participants with locally
Galapagos announces full year 2023 results and outlook for 2024
GLPG
22 Feb 24
myeloma (rrMM) First patients dosed in the PAPILIO-1 Phase 1/2 study to evaluate the safety
- Prev
- 1
- Next